By Fineline Cube LaNova Medicines Ltd., a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented Phase II clinical data for its innovative CLDN18.2-targeting antibody-drug conjugate (ADC) LM-302 in the first-line treatment of gastric or gastroesophageal junction adenocarcinoma at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results demonstrated that LM-302 combined with a PD-1 monoclonal antibody (with or without chemotherapy) achieved median progression-free survival (PFS) of 15.18–15.21 months in patients with CLDN18.2 expression ≥25%, with the doublet regimen (LM-302 + PD-1) showing comparable efficacy to the triplet but superior tolerability.
Clinical Trial Results
| Patient Population | Regimen | Median PFS | Median OS | OS Event Rate |
|---|---|---|---|---|
| Overall Population | Doublet (LM-302 + PD-1) | 10.68 months | Not reached | 45.2% (14/31) |
| Triplet (LM-302 + PD-1 + chemo) | 12.55 months | Not reached | 26.9% (7/26) | |
| CLDN18.2 ≥25% | Doublet (LM-302 + PD-1) | 15.18 months | 18.30 months | 45.2% (14/31) |
| Triplet (LM-302 + PD-1 + chemo) | 15.21 months | 18.14 months | 26.9% (7/26) |
Drug Profile & Mechanism of Action
- Molecule: LM-302 – CLDN18.2-targeting antibody-drug conjugate (ADC)
- Structure: Recombinant humanized monoclonal antibody conjugated to MMAE (monomethyl auristatin E) toxin
- Dual Mechanism:
- Precise targeting of CLDN18.2-positive tumor cells
- Bystander effect via MMAE payload killing surrounding tumor cells with low/heterogeneous CLDN18.2 expression
- Immunogenic Cell Death (ICD): Induces ICD, creating synergistic antitumor effect when combined with PD-1 monoclonal antibody
- Development Status: Independently developed by LaNova Medicines, subsidiary of Sino Biopharmaceutical
Strategic Clinical Implications
The Phase II data reveals several critical insights for gastric cancer treatment:
- Doublet Superiority: LM-302 + PD-1 doublet demonstrates comparable efficacy to triplet regimen with better tolerability, supporting chemotherapy-free first-line treatment
- Biomarker Optimization: CLDN18.2 ≥25% threshold identifies optimal patient population with 15+ month PFS
- Novel Mechanism: First CLDN18.2 ADC to demonstrate bystander effect and ICD induction in gastric cancer
- Treatment Paradigm: Potential to establish new standard of care in CLDN18.2-positive gastric/GEJ adenocarcinoma
“This Phase II data represents a significant advance in the treatment of CLDN18.2-positive gastric cancer,” said Dr. Li Wei, Chief Executive Officer of LaNova Medicines. “The comparable efficacy between doublet and triplet regimens, combined with superior tolerability of the chemotherapy-free approach, provides a compelling rationale for large-scale Phase III development of LM-302 plus PD-1 inhibitor as a new first-line standard.”
Market Opportunity & Competitive Landscape
The results position LM-302 to address a substantial unmet need in gastric cancer:
- Target Population: CLDN18.2-positive gastric/GEJ adenocarcinoma represents approximately 30–40% of cases in Asian populations
- Addressable Market: Estimated 40,000–50,000 eligible patients annually in China alone
- Competitive Differentiation: First CLDN18.2 ADC to combine bystander effect, ICD induction, and PD-1 synergy
- Global Potential: Data supports international regulatory filings and partnership opportunities
Industry analysts view the 15-month PFS in biomarker-selected patients as practice-changing, with potential peak annual sales of $500 million–$800 million globally if Phase III confirms these results.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for LM-302. Actual results may differ due to Phase III trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech